{"a": [["Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy", "2013"], ["Prospective randomized controlled study of intravitreal injection of 0.16 mg bevacizumab one day before surgery for proliferative diabetic retinopathy", "2014"], ["Prospective, randomized, multicentre, open\u2010label, phase II/III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy (PROTEUS)", "2014"], ["Pre\u2010operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: results of the Pan\u2010American Collaborative Retina Study (PACORES) Group", "2014"], ["Prevention of macular edema In patients with diabetic retinopathy undergoing cataract surgery", "2014"], ["Retinopathy in diabetes", "2006"], ["Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals", "2006"], ["Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan\u2010American Collaborative Retina Study Group at 6\u2010month follow\u2010up", "2007"], ["Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy", "2006"], ["Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment", "2006"], ["Vascular endothelial growth factor receptor\u20101 modulates vascular endothelial growth factor\u2010mediated angiogenesis via nitric oxide", "2001"], ["Manipulating angiogenesis in medicine", "2004"], ["Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy", "2006"], ["Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22", "1996"], ["A pilot study of multiple intravitreal injections of ranibizumab in patients with center\u2010involving clinically significant diabetic macular edema", "2006"], ["A phase II randomized double\u2010masked trial of pegaptanib, an anti\u2010vascular endothelial growth factor aptamer, for diabetic macular edema", "2005"], ["Risk factors for high\u2010risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18", "1998"], ["Meta\u2010analysis in clinical trials", "1986"], ["Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings", "1978"], ["Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report no. 5", "1981"], ["Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group", "1981"], ["Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two\u2010year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group", "1985"], ["Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group", "1985"], ["Grading diabetic retinopathy from stereoscopic color fundus photographs\u2010\u2010an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group", "1991"], ["Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group", "1991"], ["Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group", "1991"], ["New visual acuity charts for clinical research", "1982"], ["Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes", "2000"], ["How to identify randomized controlled trials in MEDLINE: ten years on", "2006"], ["GRADEpro", "2014"], ["Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema", "2006"], ["What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?", "2002"], ["Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011", "2011"], ["Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty\u2010four\u2010week results of a multicenter randomized clinical study", "2006"], ["The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years", "1984"], ["Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy", "1988"], ["Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?", "1989"], ["Effect of pregnancy on progression of diabetic retinopathy", "1990"], ["Blood pressure control and diabetic retinopathy", "2002"], ["The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study", "2002"], ["Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes", "2002"], ["Intravitreal triamcinolone for refractory diabetic macular edema", "2002"], ["Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy", "2006"], ["The natural course of microalbuminuria in insulin\u2010dependent diabetes: a 10\u2010year prospective study", "1995"], ["Ten\u2010years incidence of visual loss in a diabetic population", "1994"], ["Cigarette smoking and ten\u2010year progression in diabetic retinopathy", "1996"], ["Induction of vascular endothelial growth factor by platelet\u2010activating factor and platelet\u2010derived growth factor is downregulated by corticosteroids", "1997"], ["Global data on visual impairment in the year 2002", "2004"], ["Review Manager (RevMan)", "2014"], ["A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema", "2007"], ["Cyclooxygenase\u20102 in human and experimental ischemic proliferative retinopathy", "2003"], ["Complications in patients after intravitreal injection of bevacizumab", "2008"], ["Anti\u2010vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy", "2011"], ["Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage", "2006"], ["Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011", "2011"], ["Intensive blood\u2010glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group", "1998"], ["Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group", "1998"], ["Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study", "2002"], ["Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study", "2003"], ["Antiangiogenic therapy with anti\u2010vascular endothelial growth factor modalities for diabetic macular oedema", "2012"], ["Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales", "2003"], ["Twelve\u2010month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan\u2010American Collaborative Retina Study Group (PACORES)", "2008"], ["Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta\u2010analysis of randomized controlled trials", "2013"]], "ex": [["Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy", "2009"], ["Intravitreal bevacizumab and panretinal photocoagulation as combined treatment in proliferative diabetic retinopathy", "2010"], ["Injection of intravitreal Avastin before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy", "2007"], ["Pegaptanib in diabetic retinopathy: improvements in diabetic macular edema, retinal neovascularization, and diabetic retinopathy severity", "2006"], ["Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy", "2010"], ["Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage", "2009"], ["Long\u2010term effects of ranibizumab on diabetic retinopathy severity and progression", "2012"], ["Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy", "2009"], ["Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)", "2006"], ["Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study", "2009"], ["Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy", "2012"], ["A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12\u2010month data: report 2", "2010"], ["Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy", "2008"], ["Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema", "2008"], ["Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high\u2010risk proliferative diabetic retinopathy", "2009"], ["Varying doses of intravitreal bevacizumab (Avastin) for the treatment of proliferative diabetic retinopathy", "2007"], ["Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high\u2010risk proliferative diabetic retinopathy (IBeHi study)", "2008"], ["Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy", "2009"], ["Avastin combined with vitreous cavity injection of triamcinolone acetonide in treatment of diabetic retinopathy with macular edema", "2010"]], "in": [["Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial", "2009"], ["The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy", "2011"], ["Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study", "2009"], ["Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy", "2010"], ["Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy", "2010"], ["Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy", "2013"], ["Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy", "2008"], ["Comparison of panretinal photocoagulation (PRP) with PRP plus intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy", "2009"], ["Intravitreal bevacizumab versus panretinal photocoagulation for treatment\u2010na\u00efve proliferative and severe nonproliferative diabetic retinopathy", "2012"], ["Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage", "2011"], ["Treatment of proliferative diabetic retinopathy with intravitreal pegaptanib vs. panretinal photocoagulation", "2007"], ["Bevacizumab\u2010augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double\u2010masked clinical trial", "2008"], ["Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy", "2007"], ["Structural and functional assessment of macula in patients with high\u2010risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial", "2013"], ["Panretinal photocoagulation versus intravitreal injection retreatment pain in high\u2010risk proliferative diabetic retinopathy", "2013"], ["Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)", "2008"], ["Angiofibrotic response to vascular endothelial growth factor Inhibition in diabetic retinal detachment", "2012"], ["Intravitreal Avastin as an adjunct in patients with proliferative retinopathy undergoing pars plana vitrectomy", "2013"]]}